{
  "main_header": {
    "sid": 1110805,
    "name": "BioSyent, Inc.",
    "stock_name": "BioSyent, Inc.",
    "full_name": "BioSyent, Inc.",
    "name_url": "stocks-analysis/biosyent-inc",
    "exchange": 32,
    "exchangecode": "TSX",
    "country_id": 1,
    "currency": "CAD",
    "cmp": "11.95",
    "chg": 0.12,
    "chgp": "1.01%",
    "dir": 1,
    "prev_price": "11.83",
    "mcapval": "128.55",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P/TSX 60",
    "isin": "CA0906901081",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "2.16 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/biosyent-inc-1110805-32&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "BioSyent Adjusts Valuation Amid Strong Financial Performance and Growth Indicators",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/biosyent-upgraded-to-buy-as-valuation-score-improves-to-attractive-3640138",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/BioSyentInc_mojoScore_3640138.png",
        "date": "2025-10-23 15:21:27",
        "description": "BioSyent, Inc., a small-cap pharmaceutical company, has recently experienced an evaluation adjustment reflecting its strong financial profile. Key metrics include a 21.97% return on equity, impressive operating cash flow of CAD 8.92 million, and a favorable return on capital employed, highlighting its solid market position and financial health."
      }
    ],
    "total": 1,
    "sid": "1110805",
    "stock_news_url": "https://www.marketsmojo.com/news/biosyent-inc-1110805"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

BioSyent Adjusts Valuation Amid Strong Financial Performance and Growth Indicators

2025-10-23 15:21:27

BioSyent, Inc., a small-cap pharmaceutical company, has recently experienced an evaluation adjustment reflecting its strong financial profile. Key metrics include a 21.97% return on equity, impressive operating cash flow of CAD 8.92 million, and a favorable return on capital employed, highlighting its solid market position and financial health.

Read More

View All News